Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.
Identifieur interne : 000139 ( PubMed/Curation ); précédent : 000138; suivant : 000140Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.
Auteurs : Juan Sebastian Yakisich [États-Unis] ; Yogesh Kulkarni [États-Unis] ; Neelam Azad [États-Unis] ; Anand Krishnan V. Iyer [États-Unis]Source :
- Stem cells international [ 1687-966X ] ; 2017.
Abstract
The presence of highly resistant cancer cells and the toxicity to normal cells are key factors that limit chemotherapy. Here, we used two models of highly resistant lung cancer cells: (1) adherent cells growing under prolonged periods of serum starvation (PPSS) and (2) cells growing as floating tumorspheres (FTs) to evaluate the effect of Verapamil (VP) in combination with Sorafenib (SF). Compared to cells growing under routine culture conditions (RCCs), PPPS cells or FTs were highly sensitive to short-term exposure (24 h) to VP 100 μM + SF 5 μM (VP100 + SF5). Recovery experiments exposing cells to VP100 + SF5 for 24 h followed by incubation in drug-free media for 48 h demonstrated that while PPSS as well as FT cells were unable to recover, cancer cells and the noncancerous cell line Beas-2B growing under RCCs were less sensitive and were also able to recover significantly. VP100 + SF5 induced significant changes in the expression of protein associated with apoptosis, autophagy, and to a lesser extent necroptosis. Coincubation experiments with z-VAD-FMK, necrostatin 1, or chloroquine showed evidence that necroptosis played a central role. Our data demonstrates that highly resistant cancer cells can be selectively eliminated by VP + SF and that necroptosis plays a central role.
DOI: 10.1155/2017/5987015
PubMed: 29201061
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000139
Links to Exploration step
pubmed:29201061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.</title><author><name sortKey="Yakisich, Juan Sebastian" sort="Yakisich, Juan Sebastian" uniqKey="Yakisich J" first="Juan Sebastian" last="Yakisich">Juan Sebastian Yakisich</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Kulkarni, Yogesh" sort="Kulkarni, Yogesh" uniqKey="Kulkarni Y" first="Yogesh" last="Kulkarni">Yogesh Kulkarni</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Azad, Neelam" sort="Azad, Neelam" uniqKey="Azad N" first="Neelam" last="Azad">Neelam Azad</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Iyer, Anand Krishnan V" sort="Iyer, Anand Krishnan V" uniqKey="Iyer A" first="Anand Krishnan V" last="Iyer">Anand Krishnan V. Iyer</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29201061</idno><idno type="pmid">29201061</idno><idno type="doi">10.1155/2017/5987015</idno><idno type="wicri:Area/PubMed/Corpus">000139</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000139</idno><idno type="wicri:Area/PubMed/Curation">000139</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.</title><author><name sortKey="Yakisich, Juan Sebastian" sort="Yakisich, Juan Sebastian" uniqKey="Yakisich J" first="Juan Sebastian" last="Yakisich">Juan Sebastian Yakisich</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Kulkarni, Yogesh" sort="Kulkarni, Yogesh" uniqKey="Kulkarni Y" first="Yogesh" last="Kulkarni">Yogesh Kulkarni</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Azad, Neelam" sort="Azad, Neelam" uniqKey="Azad N" first="Neelam" last="Azad">Neelam Azad</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author><author><name sortKey="Iyer, Anand Krishnan V" sort="Iyer, Anand Krishnan V" uniqKey="Iyer A" first="Anand Krishnan V" last="Iyer">Anand Krishnan V. Iyer</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA</wicri:regionArea></affiliation></author></analytic><series><title level="j">Stem cells international</title><idno type="ISSN">1687-966X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The presence of highly resistant cancer cells and the toxicity to normal cells are key factors that limit chemotherapy. Here, we used two models of highly resistant lung cancer cells: (1) adherent cells growing under prolonged periods of serum starvation (PPSS) and (2) cells growing as floating tumorspheres (FTs) to evaluate the effect of Verapamil (VP) in combination with Sorafenib (SF). Compared to cells growing under routine culture conditions (RCCs), PPPS cells or FTs were highly sensitive to short-term exposure (24 h) to VP 100 <i>μ</i>M + SF 5 <i>μ</i>M (VP100 + SF5). Recovery experiments exposing cells to VP100 + SF5 for 24 h followed by incubation in drug-free media for 48 h demonstrated that while PPSS as well as FT cells were unable to recover, cancer cells and the noncancerous cell line Beas-2B growing under RCCs were less sensitive and were also able to recover significantly. VP100 + SF5 induced significant changes in the expression of protein associated with apoptosis, autophagy, and to a lesser extent necroptosis. Coincubation experiments with z-VAD-FMK, necrostatin 1, or chloroquine showed evidence that necroptosis played a central role. Our data demonstrates that highly resistant cancer cells can be selectively eliminated by VP + SF and that necroptosis plays a central role.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29201061</PMID><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1687-966X</ISSN><JournalIssue CitedMedium="Print"><Volume>2017</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Stem cells international</Title><ISOAbbreviation>Stem Cells Int</ISOAbbreviation></Journal><ArticleTitle>Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.</ArticleTitle><Pagination><MedlinePgn>5987015</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2017/5987015</ELocationID><Abstract><AbstractText>The presence of highly resistant cancer cells and the toxicity to normal cells are key factors that limit chemotherapy. Here, we used two models of highly resistant lung cancer cells: (1) adherent cells growing under prolonged periods of serum starvation (PPSS) and (2) cells growing as floating tumorspheres (FTs) to evaluate the effect of Verapamil (VP) in combination with Sorafenib (SF). Compared to cells growing under routine culture conditions (RCCs), PPPS cells or FTs were highly sensitive to short-term exposure (24 h) to VP 100 <i>μ</i>M + SF 5 <i>μ</i>M (VP100 + SF5). Recovery experiments exposing cells to VP100 + SF5 for 24 h followed by incubation in drug-free media for 48 h demonstrated that while PPSS as well as FT cells were unable to recover, cancer cells and the noncancerous cell line Beas-2B growing under RCCs were less sensitive and were also able to recover significantly. VP100 + SF5 induced significant changes in the expression of protein associated with apoptosis, autophagy, and to a lesser extent necroptosis. Coincubation experiments with z-VAD-FMK, necrostatin 1, or chloroquine showed evidence that necroptosis played a central role. Our data demonstrates that highly resistant cancer cells can be selectively eliminated by VP + SF and that necroptosis plays a central role.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yakisich</LastName><ForeName>Juan Sebastian</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Yogesh</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azad</LastName><ForeName>Neelam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Anand Krishnan V</ForeName><Initials>AKV</Initials><Identifier Source="ORCID">0000-0002-2090-5590</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Department of Pharmaceutical Sciences, Hampton University, Hampton, VA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SC1 CA173069</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SC1 HL112630</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cells Int</MedlineTA><NlmUniqueID>101535822</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29201061</ArticleId><ArticleId IdType="doi">10.1155/2017/5987015</ArticleId><ArticleId IdType="pmc">PMC5671752</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FASEB J. 2013 Jan;27(1):13-24</Citation><ArticleIdList><ArticleId IdType="pubmed">23024375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2010 Oct 1;70(19):7723-33</Citation><ArticleIdList><ArticleId IdType="pubmed">20841476</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2011 May 6;8(5):486-98</Citation><ArticleIdList><ArticleId IdType="pubmed">21549325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2013 May;143(5 Suppl):e30S-e39S</Citation><ArticleIdList><ArticleId IdType="pubmed">23649444</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Drug Discov Technol. 2015;12(1):3-20</Citation><ArticleIdList><ArticleId IdType="pubmed">26033233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2017 Aug;232(8):2033-2043</Citation><ArticleIdList><ArticleId IdType="pubmed">27504932</ArticleId></ArticleIdList></Reference><Reference><Citation>Onco Targets Ther. 2015 Dec 23;9:49-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26730203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell J. 2015 Winter;16(4):494-505</Citation><ArticleIdList><ArticleId IdType="pubmed">25685740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2013 Oct;12 (10 ):2121-34</Citation><ArticleIdList><ArticleId IdType="pubmed">23960095</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncol Rep. 2016 Feb;35(2):878-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26573786</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Nov 20;8(11):e79798</Citation><ArticleIdList><ArticleId IdType="pubmed">24278179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2011 Mar 4;144(5):646-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Aug 21;138(4):645-659</Citation><ArticleIdList><ArticleId IdType="pubmed">19682730</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Resist Updat. 2013 Jul-Nov;16(3-5):47-59</Citation><ArticleIdList><ArticleId IdType="pubmed">23757365</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Cancer. 2014 Sep 27;14 :722</Citation><ArticleIdList><ArticleId IdType="pubmed">25260650</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Med Pharmacol Sci. 2016 May;20(10 ):2045-51</Citation><ArticleIdList><ArticleId IdType="pubmed">27249603</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncol Lett. 2015 Nov;10(5):3323-3331</Citation><ArticleIdList><ArticleId IdType="pubmed">26722334</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Oncol. 2016 Jun;12 (12 ):1517-27</Citation><ArticleIdList><ArticleId IdType="pubmed">27063568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cancer Ther. 2014 Mar;13(3):763</Citation><ArticleIdList><ArticleId IdType="pubmed">24615774</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 1998 Apr;77(7):1155-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9569055</ArticleId></ArticleIdList></Reference><Reference><Citation>CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71</Citation><ArticleIdList><ArticleId IdType="pubmed">24890451</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells. 2009 Aug;27(8):1722-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19544433</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008 Aug 27;3(8):e3077</Citation><ArticleIdList><ArticleId IdType="pubmed">18728788</ArticleId></ArticleIdList></Reference><Reference><Citation>Stem Cells Int. 2016;2016:5603135</Citation><ArticleIdList><ArticleId IdType="pubmed">26880969</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Death Differ. 2013 Feb;20(2):185-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23197293</ArticleId></ArticleIdList></Reference><Reference><Citation>Neoplasia. 2015 Jan;17(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25622895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2017 Sep;232(9):2280-2286</Citation><ArticleIdList><ArticleId IdType="pubmed">27925198</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Oncol. 2016 Jul;49(1):99-110</Citation><ArticleIdList><ArticleId IdType="pubmed">27177126</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 2010 May;42(5):578-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19556603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Med Rep. 2010 Jul-Aug;3(4):555-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21472278</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(5):e19823</Citation><ArticleIdList><ArticleId IdType="pubmed">21625531</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29201061
|texte= Selective and Irreversible Induction of Necroptotic Cell Death in Lung Tumorspheres by Short-Term Exposure to Verapamil in Combination with Sorafenib.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29201061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |